Opinions
Richard Croft
Delcath Systems
DCTH-Q
COMMENT
Feb 11, 2011
Will have an FDA decision in July. Whether they get approval or not, there will be a huge move up or down. Options strategy? Market knows this is going to have an impact so this gets priced into the options. Very difficult to do this.
$11.040
Stock price when the opinion was issued
Consumer Products
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Liver cancer treatment. They isolate the liver and then pump more chemo to kill cancer cells. Survivor rate has gone from 4 to 23 months. Market potential is about 5-6 billion globally. Stock dropped when a scientist said it wouldn't work but FDA protocol showed results were significant.
Consumer Products